Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.

Critical reviews in oncology/hematology - 1 Sept 2017

Russo A, Franchina T, Ricciardi G R R, Smiroldo V, Picciotto M, Zanghì M, Rolfo C, Adamo V

Abstract excerpt

The therapeutic landscape of Non Small Lung Cancer (NSCLC) has been profoundly changed over the last decade with the clinical introduction of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) and the discovery of EGFR activating mutations as the major predictive factor to these agents. Despite impressive clinical activity against EGFR-mutated NSCLCs, the benefit seen with 1st and 2nd...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 28807234
DOI: 10.1016/j.critrevonc.2017.07.003

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.PMID 28807234Read ↗

Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer.Semantic proximity Read ↗

Emerging treatment for advanced lung cancer with EGFR mutation.Semantic proximity Read ↗

EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)Semantic proximity Read ↗

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.Semantic proximity Read ↗

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.Semantic proximity Read ↗

Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.Semantic proximity Read ↗

EGFR-mutant NSCLC: emerging novel drugs.Semantic proximity Read ↗

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.Semantic proximity Read ↗

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.Semantic proximity Read ↗

EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.Semantic proximity Read ↗

The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.Semantic proximity Read ↗

EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.